Home LiteratureArticle Details
PMID: 1905784 Published · ppublish English Comparative Study Journal Article

A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties.

Molecular immunology ·Vol. 28 ·No. 4-5 ·1991-00-00 ·Pages 489-98

Padlan EA

Abstract

It is proposed to reduce the immunogenicity of allogeneic antibody variable domains, while preserving ligand-binding properties, by reducing their antigenicity through replacement of the exposed residues in the framework regions which differ from those usually found in host antibodies. The results of a comparison of representative murine antibody sequences with those of human origin suggest that the number of residues that need to be replaced to "humanize" those antibodies could be small.

MeSH Terms
Amino Acid Sequence Animals Antibodies, Anti-Idiotypic/immunology Binding Sites, Antibody/immunology Humans Immunoglobulin Heavy Chains/immunology Immunoglobulin Light Chains/immunology Immunoglobulin Variable Region/immunology Mice Models, Molecular Molecular Sequence Data Protein Conformation Solvents Species Specificity Structure-Activity Relationship
Chemicals
Antibodies, Anti-Idiotypic Immunoglobulin Heavy Chains Immunoglobulin Light Chains Immunoglobulin Variable Region Solvents
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Padlan E A
Laboratory of Molecular Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892.
Article Info
Journal
Molecular immunology
Abbr.
Mol Immunol
ISSN
0161-5890
Published
1991-00-00
Pages
489-98
Language
English
Region
England
NLM ID
7905289
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com